Azacitidine associated with Valproic acid — Competitive Intelligence Brief

Azacitidine associated with Valproic acid (Azacitidine associated with Valproic acid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hypomethylating agent. Area: Oncology.

phase 2 Hypomethylating agent DNA methyltransferases Oncology Small molecule

Target snapshot

Azacitidine associated with Valproic acid (Azacitidine associated with Valproic acid) — Assistance Publique - Hôpitaux de Paris. Azacitidine is a hypomethylating agent that works by inhibiting DNA methyltransferases, leading to increased expression of tumor suppressor genes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Azacitidine associated with Valproic acid TARGET	Azacitidine associated with Valproic acid	Assistance Publique - Hôpitaux de Paris	phase 2	Hypomethylating agent	DNA methyltransferases
Tucidinostat, Azacitidine combined with CHOP	Tucidinostat, Azacitidine combined with CHOP	Peking Union Medical College Hospital	phase 3	Histone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen	Histone deacetylases, DNA methyltransferases
Decitabine and cedazuridine	Decitabine and cedazuridine	Race Oncology Ltd	marketed	Hypomethylating agent	DNA methyltransferase (DNMT)
Gilteritinib + Azacitidine + Venetoclax	Gilteritinib + Azacitidine + Venetoclax	Institute of Hematology & Blood Diseases Hospital, China	phase 3	FLT3 inhibitor + hypomethylating agent + BCL-2 inhibitor combination	FLT3, DNA methyltransferase, BCL-2
Decitabine plus HAAG regimen	Decitabine plus HAAG regimen	The First Affiliated Hospital of Soochow University	phase 3	Hypomethylating agent combined with chemotherapy regimen	DNA methyltransferase (DNMT)
Decitabine/Cedazuridine	Decitabine/Cedazuridine	Astex Pharmaceuticals, Inc.	phase 3	DNA methyltransferase inhibitor; hypomethylating agent	DNA methyltransferase (DNMT)
ASTX727	ASTX727	Taiho Oncology, Inc.	phase 3	Hypomethylating agent	DNA methyltransferase (DNMT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hypomethylating agent class)

1. AbbVie (prior sponsor, Abbott) · 1 drug in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. Bio-Path Holdings, Inc. · 1 drug in this class
4. Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias · 1 drug in this class
5. Otsuka Australia Pharmaceutical Pty Ltd · 1 drug in this class
6. Race Oncology Ltd · 1 drug in this class
7. Shirley Ryan AbilityLab · 1 drug in this class
8. Taiho Oncology, Inc. · 1 drug in this class